Novo Nordisk’s CagriSema for Obesity and Type 2 Diabetes Shows Superior Results in REDEFINE 2 Trial
CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim.
CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim.
Rapid weight reduction might raise the risk of osteoporosis and reduce muscular mass. However, there is now excellent news for those who may be at danger when taking weight loss medications. According to a recent study from Aarhus University, the adverse effects can be mitigated by the medication bimagrumab.
In 2022–2023, the researchers found people diagnosed with obesity without diabetes using a nationwide sample of medical insurance claims data from over 17 million persons with private insurance.